One of the most anticipated sessions dissects the action of GLP-1 receptor agonists across different stages of life. Originally developed for type 2 diabetes, these incretin mimetics—which amplify glucose-dependent insulin secretion, decelerate gastric emptying, and act directly on hypothalamic appetite circuits—have since been repurposed as powerful anti-obesity agents. However, clinicians now recognize that their effects are not uniform: in adolescents, where bone accrual and linear growth are still underway, the catabolic state induced by profound caloric restriction may have underappreciated consequences. At the other end of the lifespan, older adults on GLP-1 therapy risk accelerating the loss of lean muscle mass, a phenomenon already shadowed by sarcopenia. The session will present new data examining whether age-adjusted dosing strategies or concurrent nutritional interventions can uncouple fat loss from erosion of functional tissue.

The conference also takes aim at the often misunderstood universe of food additives. Despite their ubiquity, the toxicological framework used to evaluate their safety remains opaque to the public. A dedicated symposium will walk through the risk assessment pipeline—from establishing a no-observed-adverse-effect level in animal models to deriving an acceptable daily intake with built-in uncertainty factors. Speakers will explore how emerging evidence on metabolic endotoxemia and gut microbiota perturbations is challenging traditional safety margins, and they will debate whether existing regulations are nimble enough to address cumulative exposure and mixture effects that fall outside classical single-compound toxicology.

Geriatric nutrition receives a nuanced spotlight in a session navigating the inherent tension between cardiometabolic risk reduction and the preservation of functional capacity. For older adults, aggressive caloric restriction can improve lipid profiles and glycemic control, yet simultaneously trigger a decline in muscle protein synthesis that feeds into the frailty phenotype. Presenters will unpack the concept of anabolic resistance—the blunted muscle response to dietary amino acids seen with aging—and review trials testing whether higher protein intakes, strategic meal timing, or targeted amino acid supplementation can harmonize these competing goals.

The “food as medicine” paradigm, once a grassroots rallying cry, now comes armed with randomized clinical trial data. Researchers will report outcomes from produce prescription programs and medically tailored meal interventions deployed in diverse healthcare settings, scrutinizing endpoints such as HbA1c, hospital readmission rates, and food security metrics. The mechanistic thread weaving through these studies often leads to the gut microbiome, where shifts in short-chain fatty acid-producing bacteria appear to mediate some of the metabolic improvements. Attendees will hear how pragmatic trials are refining implementation strategies for integrating dietary interventions into electronic health records and reimbursement models.

Another symposium tackles two of the most heated debates in nutrition simultaneously: whether the clock matters as much as the calorie, and whether ultra-processed foods are intrinsically harmful. Chrononutrition research has revealed that peripheral clocks in the liver, muscle, and adipose tissue are entrained by feeding signals, meaning late-night eating can uncouple these oscillators from the central pacemaker in the suprachiasmatic nucleus, impairing insulin sensitivity and lipid oxidation. When overlaid with the hyperpalatability and altered food matrix of ultra-processed products, the metabolic disruption may be amplified. New data will probe whether the detrimental effects of ultra-processed foods are partially a function of the timing of their consumption, potentially opening a new axis for dietary interventions that manipulate both what and when we eat.

The developmental origins of health and disease take center stage in a session on pregnancy and early childhood. Epigenetic programming during the first thousand days—from conception through a child’s second birthday—can set lifelong trajectories for metabolic health, neurodevelopment, and immune function. Presenters will share findings linking maternal dietary patterns, micronutrient status, and exposure to endocrine-disrupting chemicals with offspring outcomes, and they will evaluate the evidence for interventions such as omega-3 fatty acid supplementation during pregnancy or responsive feeding practices in infancy to mitigate risk.

Beyond the individual sessions, NUTRITION 2026 will feature prestigious award lectures honoring scientists whose work defined fields, and a policy forum connecting discovery to the Dietary Guidelines for Americans. The meeting arrives as the Biden administration’s White House Conference on Hunger, Nutrition, and Health continues to galvanize federal action, making the translational dialogue between laboratory, clinic, and Capitol Hill especially urgent. For journalists, the conference provides early access to embargoed, high-impact research, on-site press facilities, and personalized interview arrangements with leading investigators, ensuring that the science served up here can quickly reach the public plate.

Subject of Research: NUTRITION 2026, the annual meeting of the American Society for Nutrition, featuring sessions on GLP-1 therapies, food additives, geriatric nutrition, food as medicine, chrononutrition, ultra-processed foods, and early-life nutrition.
Article Title: New Insights on GLP-1 Drugs, Ultra-Processed Foods, and Food as Medicine to Take Center Stage at Nutrition Science Conference
News Publication Date: 2025-06-29
Web References:
https://nutrition.org/meeting/
https://nutrition2026.eventscribe.net/index.asp?sessionTarget=1805306
https://nutrition2026.eventscribe.net/index.asp?sessionTarget=1814912
https://nutrition2026.eventscribe.net/index.asp?sessionTarget=1833550
References:
NUTRITION 2026 Program, American Society for Nutrition.
Image Credits: